Sebastien J. Hotte, MD, FRCPC - An Integrated Approach to Optimizing Radioligand Therapy and Bone Health Management in mCRPC

Please visit answersincme.com/NZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sebastien J. Hotte, MD, FRCPC. In this activity, an expert in oncology discusses radioligand therapy for metastatic castration-resistant prostate cancer. Upon completion of this activity, participants should be better able to: Evaluate how the current guidelines and evidence may inform the sequencing of radioligand therapies in patients with metastatic castration-resistant prostate cancer (mCRPC); Apply evidence-based approaches to optimally sequence radioligand therapies in patients with mCRPC; and Identify strategies to optimize bone health management in patients with mCRPC.